Your browser doesn't support javascript.
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung T; Delic-Sarac, Marina; Hestdalen, Malu Lian; Brodin, Ellen; Rustad, Even Holth; Dai, Ke-Zheng; Vaage, John Torgils; Nissen-Meyer, Lise Sofie Haug; Sund, Fredrik; Wader, Karin F; Bjornevik, Anne T; Meyer, Peter A; Nygaard, Gro O; König, Marton; Smeland, Sigbjørn; Lund-Johansen, Fridtjof; Olweus, Johanna; Kolstad, Arne.
  • Riise J; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Blaas I; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Chopra A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Tran TT; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Delic-Sarac M; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Hestdalen ML; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Brodin E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Rustad EH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Dai KZ; Department of Hematology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Vaage JT; Hematological Research Group, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Nissen-Meyer LSH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Sund F; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Wader KF; Hematological Research Group, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Bjornevik AT; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Meyer PA; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Nygaard GO; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • König M; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Smeland S; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
  • Lund-Johansen F; Department of Oncology, St Olav University Hospital, Trondheim, Norway.
  • Olweus J; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
  • Kolstad A; Department of Oncology and Hematology, Stavanger University Hospital, Stavanger, Norway.
Br J Haematol ; 197(6): 697-708, 2022 06.
Article in English | MEDLINE | ID: covidwho-1731105
ABSTRACT
B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3-6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: CD8-Positive T-Lymphocytes / Rituximab / COVID-19 Vaccines / COVID-19 / Lymphoma Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Br J Haematol Year: 2022 Document Type: Article Affiliation country: Bjh.18149

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: CD8-Positive T-Lymphocytes / Rituximab / COVID-19 Vaccines / COVID-19 / Lymphoma Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Br J Haematol Year: 2022 Document Type: Article Affiliation country: Bjh.18149